Hidradenitis Suppurativa

This phase 2b study on brensocatib did not meet its primary or secondary efficacy endpoints, causing Insmed to discontinue their HS program.

Extension data from BE HEARD showed that patients with shorter disease duration and lower baseline severity achieved higher response rates than those with longstanding, more severe disease.

Check out exclusive expert interviews of late breaking data from AAD 2026.

54-week data from the phase 3 STOP-HS1 and STOP-HS2 trials demonstrate JAK inhibitor povorcitinib's benefit in HS.

This interview highlights phase 3 findings on sonelokimab for individuals with hidradenitis suppurativa (HS).

This Q&A highlights Dr. Alexa B. Kimball's responses to questions on the FDA approval of secukinumab for pediatric patients with hidradenitis suppurativa (HS).

This FDA approval of secukinumab (Cosentyx) for hidradenitis suppurativa (HS) represents the fourth pediatric indication for the drug.

Bimekizumab was assessed using the International Hidradenitis Suppurativa Severity Score System (IHS4) outcomes in the BE HEARD I and II studies.

New data presented at EHSF in Malta boasts a reduced proportion of patients with severe HS at 3 years.

Catch up on some of the biggest alopecia areata news headlines covered by HCPLive from 2025 with this ‘Year in Review’ summary.

This study explored the potential impact of body mass index (BMI) and smoking on patients’ risk of developing hidradenitis suppurativa.

Explore the evolving role of AI in dermatology, balancing its benefits with concerns over accuracy, bias, and the human touch in patient care.

Investigators evaluated current prescription patterns for systemic HS medications among European HS specialists and opinions on criteria for biologic upgrades.

These new data indicate a potential lack of accuracy in hospital-based data on hidradenitis suppurativa (HS) outcomes among those in nonclinical settings.

This interview highlights long-term, phase 3 data from the SUNSHINE and SUNRISE core and extension trials on secukinumab for hidradenitis suppurativa.

Panelists discuss how key research gaps include pediatric studies, understanding disease progression to enable early intervention, managing acute flares, addressing cosmetic concerns from scarring and hyperpigmentation, and highlight educational resources available through the HS Foundation, medical conferences, and specialized training programs.

In a session presented at the SDPA Fall Conference, Karan Lal, DO, spoke on the topic of GLP-1 agonist drugs for weight loss and their connection to dermatology.

Panelists discuss how the pipeline includes promising therapies like sonelokimab (an IL-17A/F nanobody with potential for better tissue penetration), various JAK inhibitors, IL-1α/β inhibitors, OX40 ligand blockers, and B-cell targeted therapies that may address disease heterogeneity and offer hope for patients with treatment-resistant disease.

Panelists discuss how they monitor patients through early follow-up visits at 1 to 3 months to assess medication access, manage cutaneous adverse effects, check liver function tests, and use educational handouts and pharmacy support to counsel patients on expected benefits vs risks while maintaining treatment adherence.

Panelists discuss how JAK inhibitors show promise for specific HS phenotypes, including patients with milder disease with inflammatory nodules, those with severe trunk/buttock disease, and systemically ill patients, and may work synergistically with IL-17 inhibitors in combination therapy for the most severe cases without additive infection risk.

Panelists discuss how secukinumab’s long-term data show sustained efficacy over 2 to 4 years with low immunogenicity, allowing patients to stop and restart therapy without loss of response—unlike TNF inhibitors—and demonstrate that some initial nonresponders improve significantly with extended treatment duration.

Panelists discuss how cutaneous adverse effects from IL-17 inhibitors, including eczematous rashes and fissures occurring in about 10% of patients, can be effectively managed with topical immunomodulators, antifungal prophylaxis, and patient counseling to maintain treatment adherence and prevent discontinuation.

Panelists discuss how 2-year bimekizumab data demonstrate that nearly half of patients achieve complete clearance (HiSCR100) with peak efficacy around 6 months, sustained improvement over time, and manageable safety concerns primarily involving cutaneous reactions like eczematous rashes that can be treated topically.

This analysis highlights the impact of dermatology consultations on HS management within acute care settings.

The FDA approved expanded indications for adalimumab-aaty (Yuflyma) and its unbranded version to include the treatment of adolescent HS and pediatric UV.